An observational study in Parkinson Disease (PD), REM Sleep Behavior Disorder (iRBD) and Neurogenic Orthostatic Hypotension, sponsored by Queen Mary University of London. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Queen Mary University of London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.
Among the 428 studies in Parkinson Disease with a site in France, this one is the 66th largest by planned enrollment of the 98 observational ones that give a count, is one of 15 that started in 2026, is one of 99 observational ones, reaches primary completion later than 47 of the 75 other live ones, and was the 423rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital Tuebingen · Sites in France, Germany, Italy and 4 more countries
Ages 35–80
Hospices Civils de Lyon · Sites in France
Ages 20–80 · Healthy volunteers
University Hospital, Grenoble · Sites in France
Ages 18–85 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
428 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 67 · Phase 3 52 · Phase 4 17
First in 1990; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 64 across the 328 interventional studies, 90 across the 98 observational. Of the 318 that completed or were terminated, 60 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 428 have an industry lead sponsor. The 10 most frequent:
Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Queen Mary University of London has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Parkinson Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT04179695University Hospital, LilleEvaluation of a New Communication Aid Tool to Favor Global Patient Centered Care | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT06401395DIAMPARKClinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING) | 2027-01-01 |
| NCT06576713University Hospital, Strasbourg, FranceCombined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism | 2027-01-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 428 studies in Parkinson Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.
Background: Everyday electronic devices may detect subtle motor and non-motor abnormalities years before the clinical diagnosis of Parkinson's disease (PD) providing opportunities for early detection.
Study aim and impact: This study aims to validate an artificial intelligence based model that provides an individualised risk of PD based on demographic, clinical, genetic and digital biomarker data (smartwatch and a phone app). An early diagnosis will allow timely interventions to manage symptoms and risk stratification of participants for early clinical trials.
Methods: 60 people at risk of PD (either with polysomnography confirmed REM sleep behaviour disorder; OR neurogenic orthostatic hypotension; OR objective hyposmia on smell test) will be recruited.
Participants will complete study assessments to provide PD risk estimation using current research clinical criteria and the artificial intelligence model. Study assessments will include:
An artificial intelligence based model (AI-PROGNOSIS model) will use these digital data in combination with demographics, clinical and genetic information to provide an individualised PD risk estimation.
Accuracy measures of the risk estimates from the current research diagnostic criteria and artificial intelligence model using the presence of abnormal dopamine DAT scan as the ground truth for PD diagnosis will be provided.
People at risk of PD due to the presence of clinical markers associated with prodromal PD including one of the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following clinical markers for PD risk:
Exclusion Criteria:
People at risk of PD defined by the presence of either polysomnography-confirmed REM sleep behaviour disorder, neurogenic orthostatic hypotension or objective hyposmia documented with smell test.
Device: Smartwatch and phone app
Wearing a smartwatch and using a mobile phone application for 6 months in order to provide digital biomarker data and additional self reported clinical information.
Classification performance of the PD risk artificial intelligence-based model
Classification performance of the model in predicting dopaminergic degeneration defined as a binary outcome: a participant will be considered to have dopaminergic degeneration if putamen specific binding ratio (SBR) on the most affected side is below 2 standard deviations of age-matched normative data or shows abnormal visual inspection by a qualified nuclear medicine specialist on dopamine transporter SPECT imaging.
Time frame: From enrolment to 6 months
Usability of study digital environment (mAI-Health phone app)
System Usability Scale (SUS) scores. The SUS includes 10 statement items regarding the usability of the study phone application that will be rated on a scale of 1 - 5 (strongly disagree - strongly agree). Range 10-50 with higher scores meaning a better outcome.
Time frame: At 6 month visit
Plan to share: Yes — After completion of the study and publication of results, study data for participants that specifically consented for this, will be made accessible in a public repository, after full anonymisation, to the research community following FAIR principles for non-commercial research purposes
Supporting information: Study protocol
Time frame: To be determined (after completion of the study and publication of the main study results).
Access criteria: Qualified investigators will be able to access fully anonymised dataset according to ethical permissions through public repository.
Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 11 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →